<DOC>
	<DOCNO>NCT01855997</DOCNO>
	<brief_summary>This Phase 4 study design collection blood biomarker sample participant complete CHB treatment least 24 week pegylated interferon alfa-2a ( Peg-IFN alfa-2a ) contain regimen least 24 week post-treatment follow-up . Participants may enrol historical study support sponsored Roche , ongoing study support sponsored Roche , general medical practice . The follow-up individual choose participate study accordance ongoing study general medical practice physician . Data whole blood deoxyribonucleic acid ( DNA ) sample collect GV28555 study available previously collect Roche Clinical Repository ( RCR ) sample use combined analysis data applicable study . Procedures include blood sample collection ( applicable participant previously consent donated RCR DNA sample ) medical record capture .</brief_summary>
	<brief_title>A Study Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B ( CHB ) Who Received Treatment With Pegasys ( Peginterferon Alfa-2a ) ± Nucleoside/Nucleotide Analogue</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Adults great equal ( ≥ ) 18 year age CHB Previously enrol Roche study treat CHB ≥24 week PegIFN ± nucleoside analogue ( lamivudine entecavir ) PegIFN ± nucleotide analogue ( adefovir ) ≥24 week posttreatment followup ; Treated general practice CHB PegIFN accord standard care line current Summary Product Characteristics ( SmPC ) /local label contraindication PegIFN therapy per local label treat PegIFN ≥24 week ≥24 week posttreatment response available time blood sample collection Hepatitis A , hepatitis C , human immunodeficiency virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>